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Objective: Recent studies have demonstrated a protective role for IL-33 against obesity-associated inflammation,
atherosclerosis and metabolic abnormalities. IL-33 promotes the production of T helper type 2 (Th2) cytokines,
polarizes macrophages towards a protective alternatively activated phenotype, reduces lipid storage and decreases
the expression of genes associated with lipid metabolism and adipogenesis. Our objective was to determine the
level of serum IL-33 in non-diabetic and diabetic subjects, and to correlate these levels with clinical (BMI and body
weight) and metabolic (serum lipids and HbA1c) parameters.
Methods: The level of IL-33 was measured in the serum of lean, overweight and obese non-diabetic and diabetic
subjects, and then correlated with clinical and metabolic parameters.
Results: Non-lean subjects had significantly (P = 0.01) lower levels of IL-33 compared to lean controls. IL-33 was
negatively correlated with the BMI and body weight in lean and overweight, but not obese (non-diabetic and
diabetic), subjects. IL-33 is associated with protective lipid profiles, and is negatively correlated with HbA1c, in
non-diabetic (lean, overweight and obese) but not diabetic subjects.
Conclusions: Our data support previous findings showing a protective role for IL-33 against adiposity and atherosclerosis,
and further suggest that reduced levels of IL-33 may put certain individuals at increased risk of developing
atherosclerosis and insulin resistance. Therefore, IL-33 may serve as a novel marker to predict those who may be
at increased risk of developing atherosclerosis.
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Obesity, characterized by an increase in adipose tissue
mass, is a major risk factor for the development of a wide
array of metabolic disorders including insulin resistance,
glucose intolerance, and type 2 diabetes mellitus [1].
Obesity can be associated with increased concentrations
of low density lipoprotein cholesterol (LDL-C) and triglyc-
erides (TGL) [2], which play an important role in the de-
velopment of atherosclerosis and coronary artery disease* Correspondence: sdermime@hotmail.com
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unless otherwise stated.(CAD) [3-6]. Obesity is associated with a state of chronic
low-grade inflammation, which plays a role in the de-
velopment of both atherosclerosis [7] and diabetes [8].
In this regard, T cells and macrophages accumulate in the
adipose tissue and secrete various proinflammatory cyto-
kines and chemokines including tumour necrosis factor-
alpha (TNF-α), interleukin-6, interleukin-8, C-reactive
protein, plasminogen activator inhibitor-1, resistin, angio-
tensinogen and monocyte chemoattractant protein-1
[9,10]. Similarly, the accumulation of macrophage-derived
foam cells [11,12] and T helper type 1 (Th1) cells within
atherosclerotic plaques [13], and the resultant chronic in-
flammation of the arterial wall, plays a key role in plaque
progression [14].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2172/15/19Interleukin-33 (IL-33), a newly identified cytokine of
the interleukin-1 (IL-1) family, is broadly expressed in
various tissue types [15,16] and is mainly present in stro-
mal cells such as endothelial, epithelial and myocardial
cells [16,17], as well as pre-adipocytes and adipocytes
[18]. The receptor for IL-33 is ST2, which is a member
of the IL-1 receptor family [15]. IL-33 has been shown
to be proinflammatory in certain conditions such as al-
lergy [19] and autoimmunity [20] and to be protective in
others such as obesity [18], atherosclerosis [21] and car-
diac fibrosis [22].
The metabolic effects of IL-33 in obesity have mostly
been investigated in murine models [16,18,21]. In this re-
gard, studies have shown that IL-33 exerts protective
metabolic effects [16,18] through several mechanisms: (1)
IL-33 decreases the expression of resistin (a mediator that
is responsible for the development of insulin resistance
and type 2 diabetes mellitus [18]), (2) leads to the accumu-
lation of protective Th2 cells and their cytokines, and (3)
leads to the polarization of resident macrophages towards
a protective alternatively activated phenotype (CD206+
M2) [16,18]. These findings were further supported by
in vitro studies showing that the treatment of murine adi-
pocytes with IL-33 induces the production of protective
Th2 cytokines (mainly IL-5 and IL-13), reduces lipid stor-
age and decreases the expression of genes associated with
lipid metabolism and adipogenesis [16,18]. Moreover, IL-
33 administration to diabetic obese (ob/ob) mice results in
reduced adiposity and fasting glucose, as well as improved
glucose and insulin tolerance [16,18]; whereas feeding
ST2-/- mice a high fat diet leads to increased body weight,
fat mass, impaired insulin secretion and glucose regulation
[16,18,21].
Similarly, studies in murine (ApoE-/-) models have re-
ported a protective role for IL-33, when administered sys-
temically, against the development of atherosclerosis and
cardiovascular disease [21]. The protective properties of
IL-33 are exerted by the induction of a potent instigation
from a pro-atherogenic Th1 to a protective Th2 pheno-
type [21], and by the expansion of suppressive CD4+
FOXP3+ ST2L+ regulatory T cells [23]. In this regard, IL-
33 increases Th2 (IL-4, IL-5, and IL-13) but decreases Th1
(IFN-γ) cytokine production, and increases total serum
immunoglobulin-A (IgA), IgE and IgG1 but decreases
IgG2a, which collectively indicate a switch from a Th1 to a
Th2 phenotype [21]. Moreover, IL-33 blocks the differen-
tiation of macrophage-derived foam cells [11], which are
responsible for the formation of atherosclerotic plaques
[12]. Mice treated intraperitoneally with IL-33 exhibit
smaller atherosclerotic lesions in the aortic sinus and have
fewer macrophages and T-cells [21]; whereas those treated
with sST2 (a decoy receptor that neutralizes IL-33)
develop larger atherosclerotic plaques when compared
to controls [21]. Anti-oxidized LDL-C antibodies arethought to be protective against the development of athero-
sclerosis by enhancing the clearance of oxLDL-C from the
circulation [24]. Indeed, a recent study has proposed a role
for IL-33 in the induction of anti-ox-LDL-C antibodies [21].
Furthermore, mice treated with IL-33 produce elevated levels
of protective anti-ox-LDL-C antibodies via an effect on B1
cells, which produce high levels of IgM autoantibodies.
Collectively, the aforementioned studies suggest a pro-
tective role for IL-33 against the development of obesity-
associated inflammation and atherosclerosis. However,
little is known about the role of IL-33 in human obesity
and its associated anomalies such as atherosclerosis. In
addition, there are no correlation studies between IL-33
and important clinical parameters such as body mass
index (BMI), serum lipids, and HbA1c. Therefore, we
sought to investigate whether obesity is associated with
lower circulating levels of IL-33, and whether IL-33 is as-
sociated with clinical parameters. Herein, we show that
IL-33 is reduced in non-lean subjects, and that IL-33 is
negatively correlated with the BMI and body weight in
lean and overweight, but not obese (non-diabetic and dia-
betic), subjects. In addition, we show that IL-33 is associ-
ated with protective lipid profiles, and is negatively
correlated with HbA1c, in non-diabetic (lean, overweight
and obese) but not diabetic subjects.
Methods
Subjects and clinical parameters
The study was approved by the ethical committee board of
the Dasman Diabetes Institute of Kuwait. Non-diabetic
(glycated hemoglobin A1c, HbA1c < 6.5) and diabetic
(physician-diagnosed, HbA1c > 6.5) adult subjects were re-
cruited, and written informed consents were obtained.
Measurements of height, weight, waist, and hip-width were
obtained and subjects were classified according to their body
mass indices (BMI, kg/m2) into lean (BMI < 25), overweight
(25 ≤BMI < 30) and obese (30 ≤BMI < 40). The waist-to-hip
ratios were calculated, and the whole-body composition in-
cluding percentage of body fat (PBF), soft lean mass (SLM)
and total body water (TBW) were measured by the use of
IOI 353 Body Composition Analyzer (Jawon Medical).
Routine laboratory measurements
Peripheral blood was obtained and the fasting glucose and
lipid profiles (TGL, total cholesterol, LDL-C, high density
lipoprotein cholesterol (HDL-C)) were analyzed using the
Siemens Dimension RXL chemistry analyzer (Diamond
Diagnostics, Holliston, MA). The level of HbA1c was deter-
mined using Variant™ (Bio-Rad, Hercules, CA). Normal
values for TGL (<1.7 mmol/l), total cholesterol (<5.2 mmol/
l), LDL-C (<3.3 mmol/l) and HDL-C (>1.03 mmol/l) were
determined based on the ‘American Heart Association’
guidelines. The characteristics of the subjects are shown in
Table 1.
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immunosorbent assay (ELISA)
A blood volume of 5 ml was collected in vacutainer
blood collection tubes and allowed to clot at room
temperature for 45 minutes. Serum was obtained by cen-
trifugation at 1000 g for 10 minutes, and then stored
at -80°C until use. The concentration of serum IL-33 was
measured using the DuoSet ELISA kit (detection limit of
the kit is 23.44 pg/ml), as per manufacturers’ instructions
(R&D Systems), with minor modifications (neat serum
samples were added to a 96-well plate coated with anti-
IL-33 capture antibody and incubated overnight at 4°C).
IL-33 values that fell below the detection limit of the kit
(< 23.44 pg/ml) were excluded from the analysis.
Statistical analysis
Statistical analysis was performed using the GraphPad Prism
software (La Jolla, CA, USA). To test whether data come
from a 'Gaussian Distribution', the 'D'Agostino-Pearson
omnibus normality test was performed; since IL-33 data
were not normally distributed, the non-parametric
Mann-Whitney test was applied to compare betweenTable 1 Physical and clinical characteristics of the study popu
Characteristics LN
(a)
Number of subjects 10
Age range (Years) 32.4 ± 9.2
Total body weight 58.5 ± 11.9
Body mass index *22.95
HbA1c (%) 5.38 ± 0.32
Fasting blood glucose (mmol/l) 4.8 ± 0.45
Total cholesterol (mmol/l) 5.14 ± 1.3
HDL-C (mmol/l) 1.35 ± 0.34




Number of subjects 1
Age range (Years) 40
Total body weight 88.5
Body mass index 24.77
HbA1c (%) 8.5
Fasting blood glucose (mmol/l) 5.6




(a) Data represent non-diabetic subjects with an HbA1c < 6.5. (b) Data represent dia
of the mean (*data that were not normally distributed are shown as medians).medians. For correlation analysis, the non-parametric
Spearman r tests were applied. A P-value of less than
0.05 was considered significant.
Results
The level of serum IL-33 was tested in a total number of
140 subjects; however, as many as 94 subjects (67%)
had IL-33 levels below the detection limit of the kit
(< 23.44 pg/ml), and therefore, due to specificity/sensi-
tivity concerns were excluded from the analyses. Only
those (46 subjects, 32%) with IL-33 levels above the detec-
tion limit of the kit were included in the data analysis.
IL-33 is reduced in non-lean subjects
The concentration of serum IL-33 was compared be-
tween lean (n = 10) and non-lean (n = 21, 8 overweight
and 13 obese) non-diabetic subjects. As shown in Figure 1a,
non-lean subjects had significantly (P = 0.01, non-
parametric Mann-Whitney test) lower concentrations
of IL-33 compared to lean controls; more specifically,
the significant difference (P = 0.003, non-parame-
tric Mann-Whitney test; the overall non-parametriclations
OW OBS Total
8 13 31
36.75 ± 7.12 43.8 ± 12.8 38.7 ± 11.35
80.2 ± 11.45 *85.4 77 ± 19.5
28.2 ± 1.67 33.4 ± 2.66 28.54 ± 5.3
5.47 ± 0.34 5.72 ± 0.32 5.55 ± 0.35
5.05 ± 0.38 5.15 ± 0.36 5.015 ± 0.41
5.2 ± 0.65 5.27 ± 1.1 5.2 ± 1.03
1.32 ± 0.34 1.15 ± 0.26 1.26 ± 0.315
3.4 ± 0.76 3.6 ± 1.0 3.43 ± 0.93
1.1 ± 0.53 1.1 ± 0.41 1.02 ± 0.46
DM OW DM OBS Total
2 12 15
53 ± 14.14 50 ± 11.7 49.5 ± 11.4
81.4 ± 11.17 95.25 ± 12.1 92.96 ± 12.2
28.97 ± 0.66 34.35 ± 2.8 33 ± 3.9
6.95 ± 0.49 8.88 ± 1.75 8.6 ± 1.7
7.22 ± 1.3 10.40 ± 4.7 9.66 ± 4.5
4.52 ± 0.54 5.01 ± 1.1 4.85 ± 1.1
0.91 ± 0.09 *1.17 *1.13
2.85 ± 0.64 2.85 ± 1.2 2.78 ± 1.1
1.55 ± 0.05 1.81 ± 0.88 1.69 ± 0.85
betic subjects with an HbA1c > 6.5. Data shown represent standard deviation
a b
c d
Figure 1 IL-33 is reduced in non-lean subjects. The concentration of serum IL-33 was measured in lean (n = 10) and non-lean (n = 21, 8
overweight and 13 obese) non-diabetic subjects. (a) Non-lean subjects had significantly (P = 0.01, non-parametric Mann-Whitney test) lower
concentrations of IL-33 compared to lean controls. The graph shows the median of the 'minimum to maximum' IL-33 values. (b) Overweight
subjects had significantly (P = 0.003, non-parametric Mann-Whitney test; the overall non-parametric Kruskal-Wallis test was P = 0.01) lower
concentrations of IL-33 compared to lean controls. The graph shows the median of the ‘minimum to maximum’ IL-33 values. (c) IL-33 is
negatively correlated with the BMI in non-diabetic subjects, which was confirmed in lean/overweight (n = 18; Spearman r = -0.76, P = 0.0003) but
not obese (n = 13; body weight: Spearman r = -0.115, P = 0.7; BMI: Spearman r = 0.08, P = 0.8) subjects. (d) IL-33 is negatively correlated with the
body weight (n = 31; Spearman r = -0.38, P = 0.034) in non-diabetic subjects, which was confirmed in lean/overweight (n = 18; Spearman r = -0.57,
P = 0.013) but not obese (n = 13) subjects.
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overweight but not obese subjects (Figure 1b).
Interestingly, diabetic obese subjects had higher
levels of IL-33 compared to non-diabetic obese;
however, it was not statistically significant (data not
shown).IL-33 is negatively correlated with BMI and body weight
in lean/overweight but not obese subjects
IL-33 was negatively correlated with body weight (n =
31; Spearman r = -0.38, P = 0.034) in non-diabetic sub-
jects. Importantly, the negative correlation was observed
between IL-33 and body weight (n = 18; Spearman
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r = -0.76, P = 0.0003) in lean/overweight but not obese
(n = 13; body weight: Spearman r = -0.115, P = 0.7;
BMI: Spearman r = 0.08, P = 0.8) subjects (Figure 1c&d).
Diabetic subjects were also analyzed for a possible cor-
relation between IL-33 and BMI as well as body weight;
however, since the diabetic group consisted mostly of
obese subjects (obese n = 12, total n = 15), the analysis was
confined to the obese group, which showed no correlation
between IL-33 and BMI or body weight in diabetic obese
(data not shown). Interestingly, in diabetic but not non-
diabetic obese, IL-33 was found to be negatively correlated
with PBF and PBF to SLM ratio (n = 7; Spearman r = -0.93,
P = 0.007), and to be positively correlated with percentage
of SLM and TBW (n = 7; Spearman r = 0.93, P = 0.007)
(Figure 2). However, since the subject’s number was very
low (n = 7), analysis of a larger group of subjects is required
to verify this finding.
IL-33 is associated with protective lipid profiles in
non-diabetic but not diabetic subjects
In non-diabetic subjects, IL-33 was positively corre-
lated with HDL-C (n = 31; Spearman r = 0.388, P =
0.03) but negatively correlated with total cholesterol
(n = 31; Spearman r = -0.356, P = 0.049), LDL-C (n = 30;
Spearman r = -0.44, P = 0.0158), TGL (n = 31; Spearman
r = -0.426, P = 0.0169) (Figure 3a), cholesterol to HDL-C
ratio (n = 31; Spearman r = -0.46, P = 0.009), LDL-C to
HDL-C ratio (n = 31; Spearman r = -0.5, P = 0.004) and
TGL to HDL-C ratio (n = 31; Spearman r = -0.44, P =
0.013) (Figure 3b). When non-diabetic obese subjects were
analyzed separately, an almost negative correlation was
found between IL-33 and cholesterol to HDL-C ratio (n =
13, Spearman r = -0.54, P = 0.058) and LDL-C to HDL-C
ratio (n = 13; Spearman r = -0.59, P = 0.03), and a positive
correlation was found between IL-33 and HDL-C (n = 13;
Spearman r = 0.59, P = 0.04) (Figure 3c).
In diabetic subjects, a positive correlation was found be-
tween IL-33 and total cholesterol (n = 15, Spearman r =
0.6, P = 0.02) as well as LDL-C (n = 15; Spearman r = 0.7,
P = 0.005) levels (Figure 4a). Similarly, when diabetic obese
subjects were analyzed separately, a positive correlation
was found between IL-33 and total cholesterol (n = 12;
Spearman r =0.71, P = 0.01) and LDL-C (n = 12; Spearman
r = 0.75, P = 0.007) (Figure 4b).
IL-33 is negatively correlated with HbA1c in non-diabetic
but not diabetic subjects
Since the aforementioned data showed that IL-33 is as-
sociated with a protective lipid profile in non-diabetic
but not diabetic subjects, we sought to investigate whether
there was any correlation between IL-33 and HbA1c in
non-diabetic and diabetic subjects. In this regard, a nega-
tive correlation (n = 31; Spearman r = -0.387, P = 0.03)was found between IL-33 and HbA1c in non-diabetic
(Figure 3b) but not diabetic subjects (data not shown).
When non-diabetic obese subjects were analyzed sepa-
rately, it was found that IL-33 is negatively correlated with
HbA1c (n = 13; Spearman r = -0.61, P = 0.02) (Figure 3c).
Discussion
Previous murine studies have shown a protective role for
IL-33 against adiposity, obesity-associated inflammation,
insulin resistance and type 2 diabetes mellitus [16,18].
The mechanisms by which IL-33 exerts these protective
effects are not fully understood, and little is known
about the role of IL-33 in human obesity and its associ-
ated complications. In the present study, we explored
the concentration of serum IL-33 in lean, overweight
and obese subjects (non-diabetic and diabetic), and per-
formed correlation analysis between IL-33 and key clin-
ical and metabolic parameters. We show for the first
time that IL-33 is reduced in non-lean subjects, and that
this reduction is more pronounced in the overweight
compared to the obese. One possible explanation for the
reduced levels of IL-33 in overweight subjects is the
presence of increased levels of the decoy receptor sST2.
Interestingly, a recent study has shown that although the
level of serum IL-33 in morbidly obese subjects is un-
altered, the level of sST2 is increased [25].
We also show that IL-33 is negatively correlated with
the BMI and body weight in non-diabetic subjects, which
was observed in lean/overweight but not obese subjects.
Similarly, no correlation was found between IL-33 and
BMI or body weight in diabetic obese. Interestingly, how-
ever, in diabetic but not non-diabetic obese, a negative
correlation was found between IL-33 and PBF and PBF to
SLM ratio, and a positive correlation with percentage of
SLM and TBW; however, since the subject’s number was
very low, a larger group of subjects need to be analyzed to
verify this finding. Nonetheless, previous studies have
shown increased concentrations of sST2 in diabetic pa-
tients [26]; thus, the lack of correlation between IL-33 and
body weight or BMI in our diabetic subjects may have
been due to increased sST2 levels.
It is well known that obesity can be associated with the
development of atherosclerosis and CAD [6]. Increased
concentrations of LDL-C and TGL play a major role in
CAD development [2]. Previous studies on murine models
have shown that IL-33 reduces the development of athero-
sclerosis through the induction of anti-oxidized LDL-C
antibodies [21]. Here, we show that IL-33 is positively cor-
related with HDL-C and negatively correlated with total
cholesterol, LDL-C, TGL, cholesterol to HDL-C ratio,
LDL-C to HDL-C ratio and TGL to HDL-C ratio in non-
diabetic subjects. When we analyzed non-diabetic obese
separately, we also found a positive correlation between
IL-33 and HDL-C and a negative correlation between
Figure 2 IL-33 is negatively correlated with PBF and PBF to SLM ratio but positively correlated with SLM and TBW in diabetic subjects.
IL-33 is negatively correlated with PBF (n = 7; Spearman r = -0.93, P = 0.007) and PBF to SLM ratio (n = 7; Spearman r = -0.93, P = 0.007), but positively
correlated with SLM (n = 7; Spearman r =0.93, P = 0.007) and TBW (n = 7; Spearman r =0.93, P = 0.007), in diabetic subjects.
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http://www.biomedcentral.com/1471-2172/15/19IL-33 and cholesterol to HDL-C ratio and LDL-C to
HDL-C ratio. These findings suggest that IL-33 may play
a protective role against the development of atheroscler-
osis by means of promoting a protective lipid profile in
non-diabetic subjects, an effect that is less pronounced in
the obese. In contrast to non-diabetic subjects, diabetic
subjects lacked any protective correlation between IL-33
and serum lipids, and interestingly, a positive correlation
was found between IL-33 and total cholesterol as well as
LDL-C levels. Similarly, when diabetic obese subjects were
analyzed separately, a positive correlation was found be-
tween IL-33 and total cholesterol and LDL-C. Therefore,while non-diabetic obese have a protective lipid pro-
file (although less pronounced than the non-obese),
diabetic obese have a pro-atherogenic lipid profile;
this may provide an explanation as to why diabetic
subjects are at increased risk of developing dyslipid-
emia and atherosclerosis. Indeed, insulin resistance is
known to be an important factor in the development
of atherosclerosis, and it has been reported that 80%
of diabetic patients fail to achieve lipid-lowering goals
[27].
Little is known about the molecular mechanisms that
are involved in the development of insulin resistance
ab
c
Figure 3 IL-33 is associated with favorable serum lipid profiles and HbA1c in non-diabetic subjects. (a) IL-33 is positively correlated with
HDL-C (n = 31; Spearman r = 0.388, P = 0.03) but negatively correlated with total cholesterol (n = 31; Spearman r = -0.356, P = 0.049), LDL-C (n = 30;
Spearman r = -0.44, P = 0.0158), and TGL (n = 31; Spearman r = -0.426, P = 0.0169) levels in non-diabetic subjects. (b) IL-33 is negatively correlated
with cholesterol to HDL-C ratio (n = 31; Spearman r = -0.46, P = 0.009), LDL-C to HDL-C ratio (n = 31; Spearman r = -0.5, P = 0.004), TGL to HDL-C
ratio (n = 31; Spearman r = -0.44, P = 0.013) and HbA1c (n = 31; Spearman r = -0.387, P = 0.03) in non-diabetic subjects. (c) IL-33 is negatively
correlated with cholesterol to HDL-C ratio (n = 13; Spearman r = -0.54, P = 0.058), LDL-C to HDL-C ratio (n = 13; Spearman r = -0.59, P = 0.03) and HbA1c
(n = 13; Spearman r = -0.61, P = 0.02), but positively correlated with HDL-C (n = 13; Spearman r = 0.59, P = 0.04), in non-diabetic obese subjects.
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lated with HbA1c in non-diabetic (including obese)
but not diabetic subjects. This suggests that IL-33
may play a role in glucose regulation and thus may
be involved in the molecular mechanisms that pro-
tect against the development of insulin resistance.
This is in line with previous findings showing that
the administration of IL-33 to diabetic obese mice
reduces fasting glucose and improves glucose and in-
sulin tolerance [16,18].Weakness of the data
A major limitation of the present study is the low num-
ber of subjects included in the data analysis due to the
majority of subjects having IL-33 levels below the detec-
tion limit of the kit, which weakened the conclusions
that could be drawn from the study.
Conclusion
Our data suggest that IL-33 is reduced in non-lean sub-
jects, and that IL-33 is negatively correlated with the
ab
Figure 4 IL-33 is positively correlated with total cholesterol and LDL-C in diabetic subjects. (a) IL-33 is positively correlated with total
cholesterol (n = 15; Spearman r = 0.6, P = 0.02) and LDL-C (n = 15; Spearman r = 0.7, P = 0.005) levels in diabetic subjects. (b) IL-33 is positively
correlated with total cholesterol (n = 12; Spearman r =0.71, P = 0.01) and LDL-C (n = 12; Spearman r = 0.75, P = 0.007) levels in obese diabetic subjects.
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subjects. Furthermore, we show that IL-33 is associated
with protective lipid profiles, and is negatively correlated
with HbA1c, in non-diabetic (lean, overweight and
obese) but not diabetic subjects. These data suggest that
reduced levels of IL-33 may put certain individuals at in-
creased risk of developing insulin resistance and athero-
sclerosis, and may serve as a novel marker to predict
those who may be at increased risk of developingatherosclerosis. However, owing to the small number of
subjects studied, we cannot draw definitive conclusions,
and further mechanistic studies are warranted.
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